Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Free Report) has been given an average rating of “Moderate Buy” by the eight research firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating and six have issued a buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $44.38.
HRMY has been the subject of several analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $52.00 target price on shares of Harmony Biosciences in a research report on Wednesday, October 2nd. Mizuho upped their price target on Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Thursday, October 10th. UBS Group assumed coverage on shares of Harmony Biosciences in a research note on Tuesday, September 10th. They set a “buy” rating and a $56.00 price objective on the stock. Finally, Raymond James restated an “outperform” rating and issued a $40.00 target price on shares of Harmony Biosciences in a research note on Thursday, October 10th.
Read Our Latest Stock Analysis on HRMY
Institutional Trading of Harmony Biosciences
Harmony Biosciences Trading Up 1.3 %
NASDAQ HRMY opened at $35.41 on Monday. The firm has a market capitalization of $2.01 billion, a price-to-earnings ratio of 15.33, a PEG ratio of 0.67 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a quick ratio of 3.09 and a current ratio of 3.13. Harmony Biosciences has a one year low of $18.79 and a one year high of $40.60. The company’s 50 day moving average price is $36.41 and its 200 day moving average price is $32.84.
Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.24. Harmony Biosciences had a net margin of 17.53% and a return on equity of 22.97%. The business had revenue of $172.80 million for the quarter, compared to the consensus estimate of $172.53 million. During the same quarter last year, the firm posted $0.56 EPS. The business’s revenue for the quarter was up 28.8% compared to the same quarter last year. On average, sell-side analysts predict that Harmony Biosciences will post 2.19 EPS for the current year.
About Harmony Biosciences
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Further Reading
- Five stocks we like better than Harmony Biosciences
- What Are Dividend Contenders? Investing in Dividend Contenders
- Is Spotify Stock Poised to Soar? Options Traders Think So
- The 3 Best Retail Stocks to Shop for in August
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Canada Bond Market Holiday: How to Invest and Trade
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.